Shortage Of Lupus Patients Challenges Growing Number Of Clinical Studies

Main Category: Lupus
Article Date: 02 Sep 2009 - 23:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:4 and a half stars

4.25 (4 votes)

Healthcare Prof:not yet rated


It has been more than 50 years since the U.S. Food and Drug Administration (FDA) last approved a new medicine specifically for lupus - when Dwight D. Eisenhower was president. Existing treatments have been "borrowed" from other disorders and the risk/benefit ratio of these treatments is far from optimal. However, hope is on the horizon. Data from a recent study of an experimental treatment showed promising results, and approximately two dozen potential new lupus therapies are in various stages of development and evaluation.

Unfortunately, biotechnology and pharmaceutical companies are finding it increasingly difficult to recruit a sufficient number of eligible people with lupus at experienced clinical trial centers to participate in their studies. This shortage of well-informed patients threatens to slow the momentum which had been building for lupus drug development.

To address this shortage of participants, the Lupus Foundation of America (LFA) will conduct a live chat on its website, http://www.lupus.org, on Wednesday, September 9 at 3:00 p.m. Eastern time, to answer questions from individuals who may be interested in lupus clinical trials. Kenneth A. Getz, a senior research fellow at the Tufts Center for the Study of Drug Development, will be the featured guest. Use this link to login to the live chat or to submit a question in advance.

Getz is the founder and Board Chair of the Center for Information and Study on Clinical Research Participation (CISCRP), and author of a nationally recognized book for patients and their advocates entitled, "Informed Consent: A Guide to the Risks and Benefits of Volunteering for Clinical Trials."

The LFA created the Center for Clinical Trials Education (CCTE) (http://www.lupus.org/clinicaltrials) to educate people with lupus about clinical trial participation, and to provide information they should know before making a decision whether to enroll in a study.

Approximately 1.5 million Americans have a form of lupus, a chronic autoimmune disease which develops when the immune system is unbalanced, causing it to become destructive to any organ or tissue in the body.

Source
Lupus Foundation of America

Article adapted by Medical News Today from original press release.
Visit our lupus section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Lupus Foundation of America. "Shortage Of Lupus Patients Challenges Growing Number Of Clinical Studies." Medical News Today. MediLexicon, Intl., 2 Sep. 2009. Web.
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/162710.php>

APA
Lupus Foundation of America. (2009, September 2). "Shortage Of Lupus Patients Challenges Growing Number Of Clinical Studies." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/162710.php.

Please note: If no author information is provided, the source is cited instead.


Lupus

What is Lupus?

Lupus is an autoimmune disease where the body's immune system becomes hyperactive and attacks normal, healthy tissue. This results in symptoms such as inflammation, swelling, and damage to joints, skin, kidneys, blood, the heart, and lungs. Read more...

Most Popular Articles



Follow Our Lupus News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Lupus Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »